New eye drops aim to soothe Sjögren's dry eye

NCT ID NCT07118241

Recruiting now Symptom relief Sponsor: Lubris Bio Pty Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a protein-based eye drop (rhPRG4) can safely relieve dry eye symptoms in people with Sjögren's syndrome. About 80 adults will receive either the active drops or a placebo for 28 days. The main goal is to see if the drops can clear corneal staining, a sign of eye surface damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: recombinant human proteoglycan 4 (rhPRG4) eye drops
What this could lead to: If it works, this could lead to a new treatment option for dry eye in people with Sjögren's syndrome, potentially improving comfort and eye health.
What could go wrong: This is a small Phase 2 trial with only 80 people, so results may not apply to everyone. The treatment may not work better than a placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SJÖGREN'S SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry eye syndrome Sjogren syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SJÖGREN'S SYNDROME

Contacts and locations

Locations

OTA
RECRUITING

Brisbane, Queensland, Australia
Queensland University of Technology
RECRUITING

Brisbane, Queensland, Australia
Sydney Eye Hospital
NOT_YET_RECRUITING

Sydney, New South Wales, Australia
Univ of New South Wales
RECRUITING

Sydney, New South Wales, Australia
University of Melbourne
RECRUITING

Melbourne, Victoria, Australia
University of the Sunshine Coast
RECRUITING

Maroochydore, Queensland, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.